Tuesday, April 21, 2015

Aratana Therapeutics, Inc.: Creating Better Lives for Pets Around the World

Just like humans, pets and animals in general, have unmet areas of medical needs. By continuously investing on its research and development division, Aratana Therapeutics, Inc. ceaselessly discovers novelty therapeutics to address serious medical conditions of animals. It was in 2010 that the business started and now has several products under various phases of clinical trials.

This Kansas City, Kansas-based business is registered as a biopharmaceutical company that is engaged in the licensing, development and commercialization of novelty therapeutics for animals, most especially to companion beasts. Aratana strongly values pets as part of the family and thus deserve the equal care. Through the years, the business has discovered and continuously develops their 15 novel therapeutics. These medications are in different stages of clinical studies. They have a strong commitment to putting the illnesses of pets to an end. These discoveries include medications for allergy, viral diseases, pain, cancer and inappetence.

The man behind the success of the company is Dr. Steven St. Peter who has decades of expertise in human health and biotechnology. With his love for pets, he aims to bring advancements in human health to improve the conditions of animals around the world. One of the greatest projects of the business is the creation of their novelty therapeutics that would redefine the treatment options of lymphoma. This disease affects millions of dogs around the world. The pharmaceutical products developed by the company are comprised of both small molecule and large molecule biologics.

Dr. Steven St. Peter continues to support the business he started as the president and director of operations. Together with his team of seasoned experts, they are set to make a difference on the lives of every pet in the world. The company continues to trade its common stocks on the NASDAQ, under the symbol PETX.

No comments:

Post a Comment